October 23, 2023
BioDigit AD Study Update and 2023 CTAD
We are thrilled to announce the completion of BioDigit AD study, a natural history study focused on developing digital and sensor-based biomarkers for early detection and tracking dementia and Alzheimer's disease.
To conduct the project, BioSensics developed a robust tool for remote monitoring of IADLs using smart tags that get attached to different objects in the home. IADLs are activities that allow an individual to live independently, such as cooking, cleaning, and laundry. The project also involved the use of 1) PAMSysTM sensors for continuous monitoring of physical activity and posture, and 2) BioDigit HomeTM for remote assessment of dual-task performance and ePRO data collection.
The first results from this study will be presented this week at the 2023 Clinical Trials on Alzheimer's Disease Conference (CTAD) in Boston, MA (Poster 121).
In addition, we will be giving three other poster presentations at CTAD related to our work in developing digital health technologies for Alzheimer's disease.
Poster 125: "Nili: Digital Health Solution for Dementia Care Coordination and Management". For more info, click here.
Poster 126: "Using Speech Biomarkers for Detection and Monitoring of Cognitive Decline". Read more about BioDigit SpeechTM.
About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials and research, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.
BioSensics is the only company that offers comprehensive end-to-end solutions and services for the acquisition of digital measures and biomarkers in clinical trials and research. BioSensics designs and validates all elements of their solutions, including wearable sensors, software, and algorithms. Our experienced research team extends complete scientific and technical consultation services, such as study design and protocol development, in addition to statistical analysis. Furthermore, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.
BioSensics has received over $50M in research and development program support from the U.S. National Institute of Health (NIH). In 2022, BioSensics was chosen by NIH to create remote measurement technologies for use in clinical trials involving people with rare diseases.